FDA Authorizes Marketing of First Cardiac Ultrasound Software That Uses Artificial Intelligence to Guide User

February 7, 2020 FDA

Today, the U.S. Food and Drug Administration authorized marketing of software to assist medical professionals in the acquisition of cardiac ultrasound, or echocardiography, images.

Previous Article
FDA’s Actions in Response to 2019 Novel Coronavirus at Home and Abroad
FDA’s Actions in Response to 2019 Novel Coronavirus at Home and Abroad

FDA is an active partner in the COVID-19 response, working closely with government and public health partne...

Next Article
FDA Expertise Advancing the Understanding of Intentional Genomic Alterations in Animals
FDA Expertise Advancing the Understanding of Intentional Genomic Alterations in Animals

FDA analysis published today advances the understanding of intentional genomic alterations in animals.